Possis bids to restore AngioJet elevation
This article was originally published in The Gray Sheet
Executive Summary
Retrospective registry data on the vascular thrombectomy system will be presented at the American College of Cardiology Annual Scientific Session in Orlando, Fla. March 6-9, the company says Feb. 22. Possis Medical attributes a drop in AngioJet sales to the September 2004 release of AiMI clinical trial results, which showed a failure of the device to reduce the size of myocardial infarctions (1"The Gray Sheet" Aug. 30, 2004, p. 9). For Q2 FY 2005 (ended Jan. 31), AngioJet sales dipped 8% year-over-year - and 7% sequentially - to $15.6 mil., Possis reports...
You may also be interested in...
AngioJet Falls Short On Prophylactic Use; Possis Fortifies Current Indication
Possis Medical will present an analysis of baseline patient characteristics that may have contributed to adverse AiMI study results at TCT 2004 in Washington, D.C. Sept. 27-Oct. 1
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.